stockrowPMGC Holdings Inc.
ELAB Healthcare Biotechnology
PMGC Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $590,100.00, down 65.5% from fiscal 2023.
- Revenue
- +147.7%
- EPS
- +98.4%
- Free cash flow
- −45.0%
Quarter to June 2026, against a year earlier
Follow ELAB
Alert me
PMGC Holdings Inc. (ELAB) EV/Sales
As of 6 November 2026, PMGC Holdings Inc. (ELAB) trades at a EV/Sales of −6.9×. Over the past ten years it has ranged from −7.9× (June 2026) to 33,012,255× (November 2023); the current reading is higher than 8% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −2.6× | — |
| FY2023 | −1.9× | — |
| FY2022 | 27,712,441× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −4.9× | — |
| Mar 2026 | −6.7× | — |
| Dec 2025 | −2.6× | — |
| Sep 2025 | −2.5× | — |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ELAB PMGC Holdings Inc. | −6.9× |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR compare | −2.8× |
| CARM Carisma Therapeutics Inc. compare | 0.0× |
| PTIX Atrinsic Inc. compare | n/m |
| ARTL Artelo Biosciences, Inc. compare | n/m |
| ABPO Abpro Holdings Inc. compare | n/m |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| LABT Lakewood-Amedex Biotherapeutics Inc. compare | n/m |
| KPTI Karyopharm Therapeutics Inc. compare | 1.3× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)